Euretina 2025
rtx1 AO retinal camera
The rtx1 AO retinal camera reveals subclinical and clinical alterations at the microscopic scale, through quick exams. It provides quantification of cone cells, RPE cells and microvascular structure. Extensively validated by 250+ published studies, rtx1 enables investigating various retinal diseases, and tracking progression as well as therapy effects over shorter timescales than OCT or AF imaging.
The rtx1 device comes to EURETINA 2025 with exciting new features, that streamline its implementation in clinical studies and trials, and extends investigations to new candidate biomarkers. We will be happy to introduce all its current capabilities with live demos.
For trial sponsors and CROs
We offer global services for a successful implementation of AO biomarkers in studies and trials, through the global clinical trial equipement network of our partner Emsere.
Meet us at EURETINA to discuss how to accelerate your developments of retinal therapies.
Contact us to plan your visit !